Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05462262 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population

Study acronym: ILLUMINATION
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Enrolling by Invitation → Active, Not Recruiting
    • Primary completion pushed from Jun 2029 to Jul 2029
    • Study completion moved earlier from Oct 2029 to Aug 2029
    v7
  2. Primary completion date: Dec 2028 to Jun 2029v6
  3. Primary completion date: Dec 2023 to Dec 2028v5 Show 5 more changesShow less
    • Trial status: Recruiting to Enrolling by Invitation
    • Study completion date: Dec 2025 to Oct 2029
    • Site details revised
    • Eligibility criteria shortened, about 1 word
    • Study description shortened, about 2 words
  4. Eligibility criteria expanded, about 2 words
    • Study description expanded, about 3 words
    • Study title expanded, about 2 words
    v4
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 2022 to Oct 10, 2022
    • Eligibility criteria expanded, about 3 words
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Current guidelines recommend moderate-intensity lipid-lowering therapy (goal for LDL-C \<2.6 mmol/L or 30%-50% reduction from baseline) for patients with intermediate 10-year ASCVD risk. In these patients, early coronary atherosclerotic plaques detected by coronary CT angiography are common, but further interventions are lacking. This study aims to analyze whether intensive lipid-lowering therapy (goal for LDL-C \<1.8 mmol/L or ≥50% reduction from baseline) could delay the progression of coronary atherosclerotic lesions and reduce the adverse cardiovascular events in these target patients.
Trial Details
NCT Number NCT05462262
Lead Sponsor Chinese Academy of Medical Sciences, Fuwai Hospital
Conditions
(from sponsor)		 Coronary Artery Disease Progression
Enrollment 2,900 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov